The largest GPO!

Pharmaceutical Net, June 9th, Shanghai, a new round of GPO procurement is about to begin
.
On June 7, the Shanghai Public Medical Institutions (Parts) Drug Centralized Bargaining Procurement Alliance Service Network released the "Shanghai Public Medical Institutions (Parts) Drug Centralized Bargaining Purchasing Alliance Drug Group Procurement and Centralized Bargaining Documents" (hereinafter referred to as the "Documents")
.
The GPO procurement scale is the largest in history.
After sorting out, 130 medical institutions participated, involving 2,754 products, including three categories of traditional Chinese medicine, chemical medicine, and biological medicine, including almost all the products used in Shanghai hospitals
.
According to other statistics, the purchase amount involved this time was 32.
5 billion yuan
.

 

Coincidentally, the second batch of Shenzhen GPO catalog procurement was officially launched a few days ago, involving 140 varieties and 154 product specifications
.
In recent years, in addition to national centralized procurement and local mass procurement, GPO is also a procurement model with a high degree of attention.
This time the Shanghai and Shenzhen GPO attacks have once again become the focus of the industry
.

 

Largest GPO

 

According to the procurement catalog attached to the "Documents", judging from the cumulative historical purchase amount, levofloxacin sodium chloride injection, ambroxol injection, metformin tablets, acarbose tablets, insulin aspart injection, glucosamine tablets, Cefuroxime axetil tablets and oxaliplatin injection are undoubtedly popular products, corresponding to a cumulative purchase amount of over 100 million yuan
.

 

Some commentators said that the scale of the Shanghai GPO was unexpected.
Almost all products with annual sales of more than 10,000 yuan were included.
If there is a trend of volume or bidding, the Shanghai market will undergo a radical reshuffle
.

 

　　Judging from the data of Shanghai sample hospitals , after the first few batches of GPOs landed, the market share of the winning bidders has changed significantly
.
Take rosuvastatin calcium tablets as an example.
In July 2018, Shanghai announced the third batch of GPO winning results
.
The only company that won the bid for rosuvastatin calcium tablets was Zhejiang Jingxin Pharmaceutical .
In 2017, the sales of Zhejiang Jingxin's rosuvastatin calcium tablets in Shanghai sample hospitals ranked third after the original research AstraZeneca and the local company Lunambate; in 2018, it rose to second; 2019 AstraZeneca, which rose to the first place in the year; sales fell to the second place in 2020, but AstraZeneca, whose sales volume greatly exceeded the second place, was mainly due to the sharp drop in its price
.
(In December 2018, in the “4+7” volume procurement , Jingxin Pharmaceutical’s rosuvastatin calcium tablets won the bid in the corresponding regions at a low price; in September 2019, the “4+7” expansion and centralized procurement , Hisun Pharmaceutical, Sandoz and Chia Tai Tianqing won the bid, and the price of rosuvastatin calcium tablets supplied to Zhejiang Jingxin in Shanghai has been reduced
.
)

 

　　Another example is aripiprazole tablets.
In July 2018, Shanghai announced the results of the third batch of GPO winning bids, which showed that Jiangsu Enhua and Shanghai Shanghai Pharmaceutical Zhongxi Pharmaceutical have won the bid
.
In 2017, Zhejiang Otsuka’s aripiprazole tablets accounted for a major share of the Shanghai sample hospital market.
Shanghai Shangyao Zhongxi Pharmaceutical’s sales were smaller than Chengdu Kanghong, and Jiangsu Enhua had no sales data
.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year
.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka
.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively
.

 

　　At present, the GPO model has been implemented in Shanghai, Shenzhen, Guangxi and other places, and the price reduction effect is significant
.
Controlling fees, reducing drug prices, and controlling the growth of medical and health expenditures are important tasks for the entire medical system.
The GPO may be rolled out in more regions in the future, and a nationwide network may be formed
.

 

　　Details are still to be clarified

 

　　In February of this year, Shanghai issued the "Trial Opinions on Building a Multi-Party Linked Drug Centralized Procurement Pattern to Encourage and Promote the City's Drug Centralized Negotiated Procurement Work", which clarified that centralized drug procurement through bargaining was included in the overall framework of the city's pharmaceutical procurement system as a guarantee for drug supply.
An important part of the system, as well as an effective supplement to the country and the city’s drug purchases
.

 

　　The "Document" reflects this idea
.
The drugs involved are Shanghai GPO acquisition before March 31, 2021.
There are normal procurement records in the "Shanghai Pharmaceutical Procurement Services and Regulation Information System", coalition medical drugs , according to the Central Purchasing, bargaining way into three categories
.
Among them, the first category of drugs are selected from the state and the city’s mass procurement, medical insurance negotiation access drugs, designated production and government-priced drugs; the second category of drugs are rescue drugs or basic drugs; the third category of drugs is in addition to the above two categories Foreign medicines
.

 

　　In terms of centralized procurement and bargaining methods, the "Document" stipulates that the first category of drugs: the selected varieties purchased by the state and this city in a large amount shall be implemented at the selected prices and related regulations
.
The state and the city with the same amount of purchase is not selected varieties, included in the scope of procurement centralized bargaining by qualified pharmaceutical production enterprise reporting, on-demand procurement; second class of drugs: a qualified drug manufacturers or pharmaceutical enterprises as a package Form declaration and centralized bargaining to ensure supply; Class III drugs: directly declared by qualified drug manufacturers for centralized bargaining and reasonable competition
.

 

　　According to the "Documents", the work process is as follows: announcement, enterprise registration, data submission, comprehensive evaluation, joint bargaining, and selection results
.
The Shanghai GPO uses comprehensive evaluations for evaluation, including drug quality evaluation, market supply evaluation, clinical professional evaluation, and price evaluation.
At the same time, Western medicines and traditional Chinese medicines are classified and reviewed, and different evaluation indicators are set
.

 

　　Regarding the requirements for joint bargaining, the "Document" pointed out that, in accordance with the principle of linking volume and price, based on comprehensive evaluation, the alliance expert group will notify relevant enterprises to carry out joint bargaining in the following situations: (1) For the proposed varieties, Where price negotiation is required; (2) After the last round of price negotiation, after the concentration of dosage forms and specifications, further price negotiation is required; for the production enterprises with a concentration of selected varieties, further price negotiation is required; (3) During the bargaining procurement period, dynamic bargaining will be adopted for the unselected varieties that are purchased by the country and this city in quantity
.

 

　　However, judging from the content of the "Document", there are still some unclear matters, such as how many companies can be included in the election for each drug? Is there a elimination system? Is there a quantity of centralized procurement drugs? Part of the recruitment details have not been announced
.
In terms of drug evaluation, in addition to the standardized evaluation basis for quality evaluation, how is the market supply evaluation evaluated? What are the latitudes of clinical professional evaluation? It is not clear at this time
.
Insiders believe that the official should have a related answer
.

　　Pharmaceutical Net, June 9th, Shanghai, a new round of GPO procurement is about to begin
.
On June 7, the Shanghai Public Medical Institutions (Parts) Drug Centralized Bargaining Procurement Alliance Service Network released the "Shanghai Public Medical Institutions (Parts) Drug Centralized Bargaining Purchasing Alliance Drug Group Procurement and Centralized Bargaining Documents" (hereinafter referred to as the "Documents")
.
The GPO procurement scale is the largest in history.
After sorting out, 130 medical institutions participated, involving 2,754 products, including three categories of traditional Chinese medicine, chemical medicine, and biological medicine, including almost all the products used in Shanghai hospitals
.
According to other statistics, the purchase amount involved this time was 32.
5 billion yuan
.

 

　　Coincidentally, the second batch of Shenzhen GPO catalog procurement was officially launched a few days ago, involving 140 varieties and 154 product specifications
.
In recent years, in addition to national centralized procurement and local mass procurement, GPO is also a procurement model with a high degree of attention.
This time the Shanghai and Shenzhen GPO attacks have once again become the focus of the industry
.

 

　　Largest GPO

 

　　According to the procurement catalog attached to the "Documents", judging from the cumulative historical purchase amount, levofloxacin sodium chloride injection, ambroxol injection, metformin tablets, acarbose tablets, insulin aspart injection, glucosamine tablets, Cefuroxime axetil tablets and oxaliplatin injection are undoubtedly popular products, corresponding to a cumulative purchase amount of over 100 million yuan
.

 

　　Some commentators said that the scale of the Shanghai GPO was unexpected.
Almost all products with annual sales of more than 10,000 yuan were included.
If there is a trend of volume or bidding, the Shanghai market will undergo a radical reshuffle
.

 

　　Judging from the data of Shanghai sample hospitals , after the first few batches of GPOs landed, the market share of the winning bidders has changed significantly
.
Take rosuvastatin calcium tablets as an example.
In July 2018, Shanghai announced the third batch of GPO winning results
.
The only company that won the bid for rosuvastatin calcium tablets was Zhejiang Jingxin Pharmaceutical .
In 2017, the sales of Zhejiang Jingxin's rosuvastatin calcium tablets in Shanghai sample hospitals ranked third after the original research AstraZeneca and the local company Lunambate; in 2018, it rose to second; 2019 AstraZeneca, which rose to the first place in the year; sales fell to the second place in 2020, but AstraZeneca, whose sales volume greatly exceeded the second place, was mainly due to the sharp drop in its price
.
(In December 2018, in the “4+7” volume procurement , Jingxin Pharmaceutical’s rosuvastatin calcium tablets won the bid in the corresponding regions at a low price; in September 2019, the “4+7” expansion and centralized procurement , Hisun Pharmaceutical, Sandoz and Chia Tai Tianqing won the bid, and the price of rosuvastatin calcium tablets supplied to Zhejiang Jingxin in Shanghai has been reduced
.
)

 

　　Another example is aripiprazole tablets.
In July 2018, Shanghai announced the results of the third batch of GPO winning bids, which showed that Jiangsu Enhua and Shanghai Shanghai Pharmaceutical Zhongxi Pharmaceutical have won the bid
.
In 2017, Zhejiang Otsuka’s aripiprazole tablets accounted for a major share of the Shanghai sample hospital market.
Shanghai Shangyao Zhongxi Pharmaceutical’s sales were smaller than Chengdu Kanghong, and Jiangsu Enhua had no sales data
.
After winning the bid in July 2018, Jiangsu Enhua had some sales that year
.
In 2019 and 2020, Shanghai Shangyao Zhongxi Pharmaceutical and Jiangsu Enhua ranked second and third in sales, and their combined sales have surpassed Zhejiang Otsuka
.
The sales volume of the two companies far exceeds that of Zhejiang Otsuka, mainly because the price of the winning company is very low.
The market shares of the two companies in Shanghai in 2019 and 2020 are 52.
1% and 41.
4%, respectively
.

 

　　At present, the GPO model has been implemented in Shanghai, Shenzhen, Guangxi and other places, and the price reduction effect is significant
.
Controlling fees, reducing drug prices, and controlling the growth of medical and health expenditures are important tasks for the entire medical system.
The GPO may be rolled out in more regions in the future, and a nationwide network may be formed
.

 

　　Details are still to be clarified

 

　　In February of this year, Shanghai issued the "Trial Opinions on Building a Multi-Party Linked Drug Centralized Procurement Pattern to Encourage and Promote the City's Drug Centralized Negotiated Procurement Work", which clarified that centralized drug procurement through bargaining was included in the overall framework of the city's pharmaceutical procurement system as a guarantee for drug supply.
An important part of the system, as well as an effective supplement to the country and the city’s drug purchases
.

 

　　The "Document" reflects this idea
.
The drugs involved are Shanghai GPO acquisition before March 31, 2021.
There are normal procurement records in the "Shanghai Pharmaceutical Procurement Services and Regulation Information System", coalition medical drugs , according to the Central Purchasing, bargaining way into three categories
.
Among them, the first category of drugs are selected from the state and the city’s mass procurement, medical insurance negotiation access drugs, designated production and government-priced drugs; the second category of drugs are rescue drugs or basic drugs; the third category of drugs is in addition to the above two categories Foreign medicines
.

 

　　In terms of centralized procurement and bargaining methods, the "Document" stipulates that the first category of drugs: the selected varieties purchased by the state and this city in a large amount shall be implemented at the selected prices and related regulations
.
The state and the city with the same amount of purchase is not selected varieties, included in the scope of procurement centralized bargaining by qualified pharmaceutical production enterprise reporting, on-demand procurement; second class of drugs: a qualified drug manufacturers or pharmaceutical enterprises as a package Form declaration and centralized bargaining to ensure supply; Class III drugs: directly declared by qualified drug manufacturers for centralized bargaining and reasonable competition
.

 

　　According to the "Documents", the work process is as follows: announcement, enterprise registration, data submission, comprehensive evaluation, joint bargaining, and selection results
.
The Shanghai GPO uses comprehensive evaluations for evaluation, including drug quality evaluation, market supply evaluation, clinical professional evaluation, and price evaluation.
At the same time, Western medicines and traditional Chinese medicines are classified and reviewed, and different evaluation indicators are set
.

 

　　Regarding the requirements for joint bargaining, the "Document" pointed out that, in accordance with the principle of linking volume and price, based on comprehensive evaluation, the alliance expert group will notify relevant enterprises to carry out joint bargaining in the following situations: (1) For the proposed varieties, Where price negotiation is required; (2) After the last round of price negotiation, after the concentration of dosage forms and specifications, further price negotiation is required; for the production enterprises with a concentration of selected varieties, further price negotiation is required; (3) During the bargaining procurement period, dynamic bargaining will be adopted for the unselected varieties that are purchased by the country and this city in quantity
.

 

　　However, judging from the content of the "Document", there are still some unclear matters, such as how many companies can be included in the election for each drug? Is there a elimination system? Is there a quantity of centralized procurement drugs? Part of the recruitment details have not been announced
.
In terms of drug evaluation, in addition to the standardized evaluation basis for quality evaluation, how is the market supply evaluation evaluated? What are the latitudes of clinical professional evaluation? It is not clear at this time
.
Insiders believe that the official should have a related answer
.